Linked Life Data

20127705

Source:http://linkedlifedata.com/resource/pubmed/id/20127705

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:20127705rdf:typepubmed:Citationlld:pubmed
pubmed-article:20127705lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:20127705lifeskim:mentionsumls-concept:C0025202lld:lifeskim
pubmed-article:20127705lifeskim:mentionsumls-concept:C1704387lld:lifeskim
pubmed-article:20127705lifeskim:mentionsumls-concept:C1522642lld:lifeskim
pubmed-article:20127705lifeskim:mentionsumls-concept:C0017262lld:lifeskim
pubmed-article:20127705lifeskim:mentionsumls-concept:C1979963lld:lifeskim
pubmed-article:20127705lifeskim:mentionsumls-concept:C0851285lld:lifeskim
pubmed-article:20127705lifeskim:mentionsumls-concept:C2003903lld:lifeskim
pubmed-article:20127705lifeskim:mentionsumls-concept:C2911684lld:lifeskim
pubmed-article:20127705lifeskim:mentionsumls-concept:C0185117lld:lifeskim
pubmed-article:20127705pubmed:issue2lld:pubmed
pubmed-article:20127705pubmed:dateCreated2010-3-1lld:pubmed
pubmed-article:20127705pubmed:abstractTextThe intratumoral heterogeneity of cancer testis antigens (CTA) expression, which is driven by promoter methylation status, may hamper the effectiveness of CTA-directed vaccination of melanoma patients. Thus, we investigated whether the intratumoral heterogeneity of CTA expression is inherited at cellular level, or evolves throughout cellular replication, leading to a phenotypically unstable tumor cell population with reduced immunogenicity and/or able to escape immune control. Utilizing a previously characterized ex vivo clonal model of intratumoral heterogeneity of CTA expression in melanoma, Mel 313 MAGE-A3-low clone 5 (clone 5(M3-low)) and MAGE-A3-high clone 14 (clone 14(M3-high)) were sub-cloned and analyzed for CTA profile. Molecular assays demonstrated that levels of MAGE-A3 expression were highly conserved among generated sub-clones, as compared to parental clones. A similar behavior was identified for an extensive panel of other CTA investigated. Inherited levels of MAGE-A3 expression correlated with the extent of promoter methylation among clone 5(M3-low) and clone 14(M3-high) sub-clones analyzed. Treatment of clone 5(M3-low) with a DNA hypomethylating agent (DHA) resulted in an up-regulated expression of MAGE-A3, which was inherited at single cell level, being still detectable at day 60 in its sub-clones. Bisulfite sequencing demonstrated that also MAGE-A3 promoter methylation status was inherited among sub-clones generated from DHA-treated clone 5(M3-low) and strictly correlated with MAGE-A3 expression levels in investigated sub-clones. Similar results were obtained for additional CTA studied. Altogether our findings demonstrate that constitutive and DHA-modified CTA profiles of melanoma cells are clonally inherited throughout cellular replications, thus providing relevant insights to improve the effectiveness of CTA-based immunotherapy.lld:pubmed
pubmed-article:20127705pubmed:languageenglld:pubmed
pubmed-article:20127705pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20127705pubmed:citationSubsetIMlld:pubmed
pubmed-article:20127705pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20127705pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20127705pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20127705pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20127705pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20127705pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20127705pubmed:statusMEDLINElld:pubmed
pubmed-article:20127705pubmed:monthMaylld:pubmed
pubmed-article:20127705pubmed:issn1097-4652lld:pubmed
pubmed-article:20127705pubmed:authorpubmed-author:FonsattiEster...lld:pubmed
pubmed-article:20127705pubmed:authorpubmed-author:SigalottiLuca...lld:pubmed
pubmed-article:20127705pubmed:authorpubmed-author:CalabròLuanaLlld:pubmed
pubmed-article:20127705pubmed:authorpubmed-author:ColizziFrance...lld:pubmed
pubmed-article:20127705pubmed:authorpubmed-author:CoralSandraSlld:pubmed
pubmed-article:20127705pubmed:authorpubmed-author:AltomonteMare...lld:pubmed
pubmed-article:20127705pubmed:authorpubmed-author:MaioMicheleMlld:pubmed
pubmed-article:20127705pubmed:authorpubmed-author:FrattaElisabe...lld:pubmed
pubmed-article:20127705pubmed:authorpubmed-author:DanielliRicca...lld:pubmed
pubmed-article:20127705pubmed:authorpubmed-author:CovreAlessiaAlld:pubmed
pubmed-article:20127705pubmed:authorpubmed-author:NicolayHugues...lld:pubmed
pubmed-article:20127705pubmed:issnTypeElectroniclld:pubmed
pubmed-article:20127705pubmed:volume223lld:pubmed
pubmed-article:20127705pubmed:ownerNLMlld:pubmed
pubmed-article:20127705pubmed:authorsCompleteYlld:pubmed
pubmed-article:20127705pubmed:pagination352-8lld:pubmed
pubmed-article:20127705pubmed:meshHeadingpubmed-meshheading:20127705...lld:pubmed
pubmed-article:20127705pubmed:meshHeadingpubmed-meshheading:20127705...lld:pubmed
pubmed-article:20127705pubmed:meshHeadingpubmed-meshheading:20127705...lld:pubmed
pubmed-article:20127705pubmed:meshHeadingpubmed-meshheading:20127705...lld:pubmed
pubmed-article:20127705pubmed:meshHeadingpubmed-meshheading:20127705...lld:pubmed
pubmed-article:20127705pubmed:meshHeadingpubmed-meshheading:20127705...lld:pubmed
pubmed-article:20127705pubmed:meshHeadingpubmed-meshheading:20127705...lld:pubmed
pubmed-article:20127705pubmed:meshHeadingpubmed-meshheading:20127705...lld:pubmed
pubmed-article:20127705pubmed:meshHeadingpubmed-meshheading:20127705...lld:pubmed
pubmed-article:20127705pubmed:meshHeadingpubmed-meshheading:20127705...lld:pubmed
pubmed-article:20127705pubmed:meshHeadingpubmed-meshheading:20127705...lld:pubmed
pubmed-article:20127705pubmed:meshHeadingpubmed-meshheading:20127705...lld:pubmed
pubmed-article:20127705pubmed:meshHeadingpubmed-meshheading:20127705...lld:pubmed
pubmed-article:20127705pubmed:meshHeadingpubmed-meshheading:20127705...lld:pubmed
pubmed-article:20127705pubmed:meshHeadingpubmed-meshheading:20127705...lld:pubmed
pubmed-article:20127705pubmed:year2010lld:pubmed
pubmed-article:20127705pubmed:articleTitleEpigenetically regulated clonal heritability of CTA expression profiles in human melanoma.lld:pubmed
pubmed-article:20127705pubmed:affiliationCancer Bioimmunotherapy Unit, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico, Aviano, PN, Italy.lld:pubmed
pubmed-article:20127705pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:20127705pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:20127705lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:20127705lld:pubmed